Best place to buy AOD-9604: what the trial record actually says

Last updated 2026-07-25

Is there an FDA-approved version of AOD-9604 I can just buy?

No. There is no FDA-approved AOD-9604 product. A search of Drugs@FDA, the FDA's own database of approved drug products, turns up nothing for AOD-9604 because it was never approved for obesity or any other indication ^[1]. That single fact should reframe the whole question of "where to buy it." You're not choosing between a brand-name pharmacy price and a generic price the way you would with metformin or semaglutide. You're choosing among unapproved research-grade or compounded material with no FDA-approved reference product to compare it to. That matters for sourcing because it means there's no standard dose, no standard purity spec, and no FDA lot-release process backing any vial you'd buy. Every source is effectively making its own quality claims.

Did AOD-9604 actually work in human obesity trials?

It went through clinical development, but the weight-loss signal did not separate convincingly from placebo. A 2004 review in Current Opinion in Investigational Drugs covering AOD-9604's metabolic profile describes it as a modified fragment of human growth hormone (hGH 176-191) designed to isolate the fat-metabolizing region of the hormone while dropping the growth-promoting and diabetogenic effects ^[2]. That's the whole rationale in one sentence: take the piece of GH that seems to drive lipolysis, leave behind the piece that raises blood sugar and drives tissue growth. It's a smart hypothesis on paper. Natural GH already causes side effects like fluid retention and insulin resistance at doses needed for fat loss, so a fragment that keeps the fat-burning action without those effects would be genuinely useful. The problem is the human trial data never delivered a clean win. A 2006 survey of obesity drugs in clinical development, also in Current Opinion in Investigational Drugs, places AOD-9604 among a crowded field of candidates being tested for weight loss at the time, most of which never reached approval ^[3]. AOD-9604's developer (Metabolic Pharmaceuticals) ran Phase IIb trials in the mid-2000s, and the topline results showed weight loss too close to placebo to support an obesity drug approval. That's why, two decades later, you still can't buy it at a retail pharmacy. For the deeper mechanism story, see what does AOD-9604 actually do.

Why hasn't AOD-9604 been approved if the mechanism made sense?

Mechanism plausibility and clinical trial success are two different things, and AOD-9604 is a clean example of that gap. The fragment approach was designed to avoid GH's downsides while keeping its lipolytic action, which sounds elegant in a lab. But biology doesn't always cooperate once you're dosing real humans over months. The available literature doesn't show a large, well-controlled Phase III obesity trial with a positive, statistically separated result for AOD-9604 versus placebo. What exists in the peer-reviewed record are early mechanistic and Phase II-era reports ^[2][3], general trial-methodology pieces referencing AOD-9604 as an example compound in "Gateways to clinical trials" roundups from 2003 and 2005 that catalog drugs entering the pipeline without reporting a definitive efficacy win ^[4][5][6], and more recent reviews of peptide therapeutics in orthopaedic and sports-medicine contexts that discuss AOD-9604 alongside other unapproved peptides without concluding it has established obesity efficacy ^[7][8]. None of that adds up to "this works for fat loss in humans." It adds up to "this was studied, and development didn't lead anywhere."

So why do people still search for the best place to buy AOD-9604?

Mostly because it's cheap to make, easy to find on research-chemical sites, and the marketing language around it ("fat-burning fragment," "no GH side effects") is appealing even when the trial data isn't. Search interest doesn't track efficacy. It tracks how loudly something is marketed. If you're comparing it to other GH-axis peptides being discussed for body composition, tesamorelin actually has FDA approval for a specific indication (HIV-associated lipodystrophy), which is a meaningfully different evidence tier than AOD-9604's unapproved, placebo-level trial history. See the side-by-side in AOD-9604 vs tesamorelin if you're weighing options.

What actually separates a legitimate source from a sketchy one?

Since there's no FDA-approved product, "legitimate" doesn't mean "FDA-approved pharmacy." It means understanding the two lawful-adjacent pathways that exist for unapproved compounds and knowing that most online sellers fit neither. Under federal law, compounding pharmacies can prepare drugs from bulk substances only under specific conditions. Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353a) allows licensed pharmacists and physicians to compound a drug for an identified individual patient based on a valid prescription, but only using bulk substances that meet certain criteria, including appearing on FDA's 503A bulks list or otherwise meeting the statute's requirements ^[9]. Outsourcing facilities registered under section 503B operate under a parallel but distinct set of rules and their own bulks list ^[10][11]. FDA maintains the actual current 503A bulk drug substances list ^[12] and a list of substances nominated for possible inclusion ^[13]. AOD-9604 is not on FDA's published 503A bulks list. That means a compounding pharmacy legitimately dispensing it under an individual prescription needs to justify inclusion under the statute's other pathways, and most "buy AOD-9604" storefronts you'll find through a general web search aren't compounding pharmacies at all. They're selling it labeled "research use only," which is a legal fiction when the product is marketed and used for personal fat-loss injection.

What does "research use only" labeling actually mean for a buyer?

It means the seller is disclaiming any medical use, dosage guidance, or quality guarantee, while the actual marketing around the product (blog posts, forum threads, before/after claims) is aimed squarely at people who intend to inject it for fat loss. That gap between label and intent is exactly the kind of thing FDA's "intended use" regulation exists to address. Under 21 CFR 201.128, a product's intended use is determined by the totality of the evidence, including how it's marketed, more than what the label says ^[14]. Practically, this means: research-chemical vendors are not held to pharmaceutical manufacturing standards, don't undergo FDA inspection for this product, and offer no enforceable purity or sterility guarantee. Independent testing of research-chemical market peptides has repeatedly found products under-dosed, over-dosed, contaminated, or simply mislabeled relative to what's on the vial. There's no AOD-9604-specific published testing survey in the citations here, but the general pattern in the unregulated peptide market is well documented enough that treating any vial's printed concentration as reliable is a mistake.

Is AOD-9604 detectable in drug testing, and does that matter for sourcing decisions?

If you compete in a tested sport, this matters more than price. A 2013 study in Drug Testing and Analysis found that AOD-9604 does not interfere with or trigger the WADA hGH isoform immunoassay ^[15], meaning it isn't caught by the standard GH doping test. But separately, the World Anti-Doping Agency and sports federations classify GH fragments and analogs as prohibited, and dedicated methods for detecting peptides like this in doping control keep advancing. Analytical chemistry papers describe LC-MS/MS and ion mobility methods specifically built to catch small peptides under 2 kDa in urine, and AOD-9604, at roughly 15 amino acids, falls in that detectable size range using direct urine injection and modern mass spectrometry ^[16][17][18]. So "it doesn't show up on the standard hGH test" is true but incomplete. Sport-specific labs use different, more targeted assays now. If you're an athlete under any testing authority, sourcing decisions carry real career risk, more than health risk. Read AOD-9604 side effects and AOD-9604 contraindications before you get anywhere near a purchase decision.

What would a provider-reviewed sourcing path actually look like?

It looks like a licensed prescriber reviewing your health history, deciding whether a GH-axis peptide fits your situation at all given the honest trial record, and if so, having it filled through a pharmacy operating under 503A or 503B rules rather than a research-chemical storefront. That's a meaningfully different chain of accountability: a named pharmacy, a named prescriber, documented dosing, and someone checking for interactions and contraindications before you inject anything. AOD-9604 Co's role here is to connect you with that provider-reviewed pathway and name the fulfilling pharmacy partner when a provider determines it's appropriate, rather than selling anything directly. We don't compound or manufacture the product ourselves; we're pointing you toward the accountable route instead of a blind cart checkout. If you go this route, ask directly what bulk substance sourcing and testing standard the pharmacy uses, and don't accept vague answers.

What questions should I ask before buying from any source?

Ask what pharmacy or facility is actually compounding the product, and whether they operate under 503A or 503B ^[9][10]. Ask for a certificate of analysis specific to your lot, not a generic one pulled from a website. Ask whether a licensed prescriber has reviewed your case, or whether it's a straight online cart transaction with no clinical oversight at all. Ask what the actual evidence is for the dose being sold, since there's no FDA-approved dosing to point back to. And ask yourself honestly whether you'd accept this level of evidence (Phase II data that didn't separate from placebo, no approved product, no established long-term safety record) for any other drug you'd inject regularly. If the answer is no, that tells you something.

How does AOD-9604's evidence compare to other fat-loss peptide options?

Here's where AOD-9604 sits relative to a couple of adjacent, better-documented compounds, based on approval status and the strength of published human data.

The honest takeaway from that table: AOD-9604 sits at the weakest evidence tier of the three. That doesn't make it worthless as a research subject, but it does make "best place to buy it" a strange question to center a purchasing decision on, when the more relevant question is whether to buy it at all.

Frequently asked questions

What is the best place to buy AOD-9604 online?

There's no retail source that carries FDA-approved AOD-9604, because none exists ^[1]. The safest option is a provider-reviewed pathway where a licensed prescriber assesses you and a 503A or 503B pharmacy fills it, rather than an unregulated research-chemical storefront with no clinical oversight.

Is AOD-9604 legal to buy in the US?

It's legal to sell as a "research chemical" not intended for human use, but most marketing and use around it is clearly aimed at personal injection, which conflicts with FDA's intended-use standard under 21 CFR 201.128 ^[14]. It is not an FDA-approved drug for human consumption ^[1].

Does AOD-9604 actually cause fat loss in humans?

The peer-reviewed record doesn't show a convincing win. Early mechanistic work described the fragment rationale ^[2], and later development-stage reviews placed it among many obesity candidates that didn't reach approval ^[3]. Phase II trial results reportedly did not separate clearly from placebo, which is why no approved product followed.

Why is AOD-9604 not FDA approved?

Because its clinical trials, run in the mid-2000s by Metabolic Pharmaceuticals, did not produce weight-loss results strong enough, relative to placebo, to support an approval submission. Drugs@FDA shows no approved AOD-9604 product today ^[1].

Can a compounding pharmacy legally make AOD-9604?

Only under specific conditions. Section 503A (21 U.S.C. § 353a) requires an individual patient prescription and bulk substances meeting statutory criteria ^[9]; AOD-9604 isn't on FDA's current 503A bulks list ^[12], which limits the legitimate legal pathway for pharmacies to compound it.

Will AOD-9604 show up on a drug test?

It does not trigger the standard WADA hGH isoform immunoassay, per a 2013 study in Drug Testing and Analysis ^[15]. But newer targeted mass spectrometry methods built to detect small peptides under 2 kDa in urine can potentially catch it ^[16][17][18], so athletes under any testing authority should assume detection risk exists.

How is AOD-9604 different from regular HGH?

AOD-9604 is a synthetic fragment representing amino acids 176-191 of human growth hormone, designed to isolate the fat-metabolizing region while leaving out the parts of GH linked to tissue growth and blood sugar effects ^[2]. Whether that theoretical safety advantage translates to real fat-loss benefit in humans is unproven.

What should I ask a seller before buying AOD-9604?

Ask which pharmacy or facility compounds it and under what regulatory pathway (503A or 503B), request a lot-specific certificate of analysis, and confirm whether a licensed prescriber has reviewed your case. Vague or unanswered questions on any of these are a reason to walk away.

Is AOD-9604 the same as tesamorelin?

No. Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has positive controlled trial data for that specific population. AOD-9604 has no FDA approval and its obesity trials didn't clearly beat placebo. See AOD-9604 vs tesamorelin for a full comparison.

Are there side effects to worry about with AOD-9604?

Because there's no large, well-controlled long-term safety database, and sourcing is largely unregulated, injection-site reactions and unknown-purity contamination are practical concerns beyond whatever the drug itself does. Details are covered in AOD-9604 side effects.

Can I get AOD-9604 through a normal prescription at my pharmacy?

Not through a standard retail pharmacy, since there's no FDA-approved product to prescribe. It could theoretically be compounded under a 503A prescription pathway if a pharmacy justifies the bulk substance use, but this is not the typical "walk into CVS" scenario.

Does the research-use-only label protect me if something goes wrong?

No. That label mainly protects the seller legally by disclaiming medical use; it doesn't guarantee purity, dosing accuracy, or sterility. FDA's intended-use framework under 21 CFR 201.128 looks past the label to how a product is actually marketed and used ^[14].

Sources

1. FDA, Drugs@FDA database: No FDA-approved AOD-9604 product exists in the approved drug products database
2. PubMed PMID 15134286, Current Opinion in Investigational Drugs, 2004: AOD-9604 is a modified hGH 176-191 fragment designed to isolate fat-metabolizing action while avoiding GH's growth and diabetogenic effects
3. PubMed PMID 16625817, Current Opinion in Investigational Drugs, 2006: AOD-9604 was one of many obesity drug candidates in clinical development circa 2006, most of which did not reach approval
4. PubMed PMID 14685303, Methods and Findings in Experimental and Clinical Pharmacology, 2003: AOD-9604 appears in a 2003 catalog of drugs entering clinical trial pipelines
5. PubMed PMID 14571286, Methods and Findings in Experimental and Clinical Pharmacology, 2003: AOD-9604 appears in a second 2003 clinical trials pipeline roundup
6. PubMed PMID 15834452, Methods and Findings in Experimental and Clinical Pharmacology, 2005: AOD-9604 appears in a 2005 clinical trials pipeline roundup without a reported definitive efficacy outcome
7. PubMed PMID 41490200, JAAOS Global Research & Reviews, 2026: Recent review of therapeutic peptides in orthopaedics discusses AOD-9604 among unapproved peptides without establishing obesity efficacy
8. PubMed PMID 41966639, Sports Medicine, 2026: Review of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance covers AOD-9604's safety and efficacy status
9. 21 U.S.C. § 353a, pharmacy compounding: Section 503A allows compounding for an identified patient under a valid prescription using bulk substances meeting statutory criteria
10. 21 CFR 216.24, the 503B Bulks List: Outsourcing facilities under 503B operate under a separate bulk drug substances list and regulatory pathway
11. 21 CFR 216.23, the final 503A Bulks List: 503A compounding is restricted to bulk substances on the finalized 503A bulks list or meeting statutory exceptions
12. FDA, bulk drug substances used in compounding under section 503A: FDA maintains the current list of bulk substances that may be used under 503A compounding; AOD-9604 is not on it
13. FDA, bulk drug substances nominated for use in compounding (current list): FDA tracks nominated bulk substances under consideration for the 503A list separately from the finalized list
14. 21 CFR 201.128, meaning of intended uses: A product's intended use is determined by the totality of marketing evidence, not solely by its printed label
15. PubMed PMID 24124033, Drug Testing and Analysis, 2013: AOD-9604 does not influence or trigger the WADA hGH isoform immunoassay
16. PubMed PMID 24906629, Journal of Pharmaceutical and Biomedical Analysis, 2014: Analytical methods have been developed to detect emerging peptide therapeutics and non-approved drugs in doping controls
17. PubMed PMID 25382550, Expert Review of Proteomics, 2014: Review of methods for detecting peptidic drugs and analogs, including small GH fragments, in sports doping controls
18. PubMed PMID 26578461, Journal of Separation Science, 2016: Direct urine injection with LC and ion mobility mass spectrometry expands screening for peptides under 2 kDa